These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 14502782

  • 1. Immunohistochemical study of protein induced by vitamin K absence or antagonist II in hepatocellular carcinoma.
    Ajisaka H, Shimizu K, Miwa K.
    J Surg Oncol; 2003 Oct; 84(2):89-93. PubMed ID: 14502782
    [Abstract] [Full Text] [Related]

  • 2. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.
    Fujioka M, Nakashima Y, Nakashima O, Kojiro M.
    Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R, Wang B, Ding H, Shen H, Li Y, Chen X.
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [Abstract] [Full Text] [Related]

  • 4. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
    Nakao A, Taniguchi K, Inoue S, Takeda S, Harada A, Nonami T, Watanabe K, Takagi H.
    Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
    [Abstract] [Full Text] [Related]

  • 5. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Jang MK.
    J Clin Gastroenterol; 2009 Jun; 43(5):482-8. PubMed ID: 19197197
    [Abstract] [Full Text] [Related]

  • 6. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II.
    Yano Y, Yamashita F, Kuwaki K, Fukumori K, Kato O, Yamamoto H, Ando E, Tanaka M, Sata M.
    Liver Int; 2006 Sep; 26(7):789-95. PubMed ID: 16911460
    [Abstract] [Full Text] [Related]

  • 7. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
    Arima K, Kodama T, Suga M, Sakamoto H, Ohe Y, Yachi A.
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
    [Abstract] [Full Text] [Related]

  • 8. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S, Morishita T, Shibata J, Sato T.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [Abstract] [Full Text] [Related]

  • 9. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
    Kim MJ, Bae KW, Seo PJ, Jeong IK, Kim JH, Lee BH, Bang KT, Kim DW, Song IH.
    Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
    [Abstract] [Full Text] [Related]

  • 10. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
    Tang W, Miki K, Kokudo N, Sugawara Y, Imamura H, Minagawa M, Yuan LW, Ohnishi S, Makuuchi M.
    Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
    [Abstract] [Full Text] [Related]

  • 11. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.
    Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Nagai T, Minami Y, Ueshima K.
    Oncology; 2008 May; 75 Suppl 1():91-8. PubMed ID: 19092277
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R.
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [Abstract] [Full Text] [Related]

  • 13. [Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma].
    Yoon YJ, Han KH, Kim C, Chon CY, Moon YM, Han CH, Choi HJ, Kim YS, Han JY, Kim HS.
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):465-71. PubMed ID: 12506251
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP.
    Baek YH, Lee JH, Jang JS, Lee SW, Han JY, Jeong JS, Choi JC, Kim HY, Han SY.
    Hepatogastroenterology; 2009 Dec; 56(91-92):763-7. PubMed ID: 19621698
    [Abstract] [Full Text] [Related]

  • 15. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
    Mohamedein A, Yousif-Kadaru AG, Ahmed SA, Saida H, Zaki ZA, Eldin, Fedail SS.
    East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
    [Abstract] [Full Text] [Related]

  • 16. The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Sakon M, Monden M, Gotoh M, Kobayashi K, Kanai T, Umeshita K, Endoh W, Mori T.
    Am J Gastroenterol; 1991 Mar; 86(3):339-45. PubMed ID: 1705389
    [Abstract] [Full Text] [Related]

  • 17. Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma.
    Masuda T, Beppu T, Horino K, Komori H, Hayashi H, Okabe H, Otao R, Horlad H, Ishiko T, Takamori H, Kikuchi K, Baba H.
    J Surg Oncol; 2010 Oct 01; 102(5):490-6. PubMed ID: 19937994
    [Abstract] [Full Text] [Related]

  • 18. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Fujiyama S, Morishita T, Sagara K, Sato T, Motohara K, Matsuda I.
    Hepatogastroenterology; 1986 Oct 01; 33(5):201-5. PubMed ID: 2433199
    [Abstract] [Full Text] [Related]

  • 19. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y, Kashiwagi T, Tsutsumi H, Nagasawa M, Toyama T, Ozaki S, Naito M, Ishibashi K, Azuma M.
    Hepatogastroenterology; 1999 Oct 01; 46(28):2464-8. PubMed ID: 10522021
    [Abstract] [Full Text] [Related]

  • 20. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
    Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, Cho SY, Hong YJ, Park HY, Lee M, Jung HH, Lee KH, Jeong SH.
    Am J Gastroenterol; 2006 Sep 01; 101(9):2051-9. PubMed ID: 16848813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.